Gut microbiota and their metabolites in hemodialysis patients.
作者信息
Du Junxia, Zhao Xiaolin, Ding Xiaonan, Ren Qinqin, Wang Haoran, Han Qiuxia, Song Chenwen, Wang Xiaochen, Zhang Dong, Zhu Hanyu
机构信息
Department of Nephrology, First Medical Center of Chinese People's Liberation Army General Hospital, Nephrology Institute of the Chinese People's Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing 100853, China.
Medical School of Chinese People's Liberation Army, Beijing 100853, China.
出版信息
Chin Med J (Engl). 2025 Feb 20;138(4):502-504. doi: 10.1097/CM9.0000000000003423. Epub 2025 Jan 14.
Abstract
摘要
相似文献
1
Gut microbiota and their metabolites in hemodialysis patients.血液透析患者的肠道微生物群及其代谢产物
Chin Med J (Engl). 2025 Feb 20;138(4):502-504. doi: 10.1097/CM9.0000000000003423. Epub 2025 Jan 14.
2
Abnormalities in gut microbiota and serum metabolites in hemodialysis patients with mild cognitive decline: a single-center observational study.血液透析轻度认知下降患者肠道微生物群和血清代谢物的异常：一项单中心观察性研究。
Psychopharmacology (Berl). 2020 Sep;237(9):2739-2752. doi: 10.1007/s00213-020-05569-x. Epub 2020 Jun 30.
3
The Role of the Gut Microbiota in Complications among Hemodialysis Patients.肠道微生物群在血液透析患者并发症中的作用
Microorganisms. 2024 Sep 12;12(9):1878. doi: 10.3390/microorganisms12091878.
4
Identification of Gut Microbiome Signatures Associated with Indole Pathway in Tryptophan Metabolism in Patients Undergoing Hemodialysis.鉴定与血液透析患者色氨酸代谢中吲哚途径相关的肠道微生物组特征。
Biomolecules. 2024 May 24;14(6):623. doi: 10.3390/biom14060623.
5
Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study.膳食菊粉补充对血液透析个体肠道微生物组组成和衍生代谢物的影响：一项初步研究。
J Ren Nutr. 2021 Sep;31(5):512-522. doi: 10.1053/j.jrn.2020.10.003. Epub 2021 Jun 11.
6
Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia.肠道微生物群与血液透析贫血患者对红细胞生成素临床反应的相关性。
Front Cell Infect Microbiol. 2022 Jul 22;12:919352. doi: 10.3389/fcimb.2022.919352. eCollection 2022.
7
Changes of Gut Microbiota in Maintenance Hemodialysis Patients and Their Impact on Patient's Microinflammation Status.维持性血液透析患者肠道菌群变化及其对患者微炎症状态的影响。
Cell Mol Biol (Noisy-le-grand). 2023 Aug 31;69(8):96-101. doi: 10.14715/cmb/2023.69.8.15.
8
Decrease in Escherichia-Shigella in the gut microbiota of ESKD patients undergoing maintenance hemodialysis.接受维持性血液透析的终末期肾病患者肠道微生物群中埃希氏菌-志贺氏菌属减少。
BMC Nephrol. 2025 Feb 25;26(1):98. doi: 10.1186/s12882-025-03988-6.
9
Association of subjective global assessment of nutritional status with gut microbiota in hemodialysis patients: a case-control study.主观整体评估营养状况与血液透析患者肠道微生物群的关联：一项病例对照研究。
Nephrol Dial Transplant. 2021 May 27;36(6):1104-1111. doi: 10.1093/ndt/gfaa019.
10
A cross-sectional study on gut microbiota in patients with chronic kidney disease undergoing kidney transplant or hemodialysis.一项针对接受肾移植或血液透析的慢性肾脏病患者肠道微生物群的横断面研究。
Am J Transl Res. 2023 Mar 15;15(3):1756-1765. eCollection 2023.
本文引用的文献
1
The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review.肠道微生物群失调与粪便微生物群移植的调节：伞状综述
Front Microbiol. 2023 Nov 3;14:1286429. doi: 10.3389/fmicb.2023.1286429. eCollection 2023.
2
Higher serum trimethylamine N-oxide (TMAO) levels are associated with increased visceral fat in hemodialysis patients.血清三甲胺 N-氧化物（TMAO）水平升高与血液透析患者内脏脂肪增加有关。
Clin Nephrol. 2023 Dec;100(6):275-283. doi: 10.5414/CN111163.
3
Prevalence of Chronic Kidney Disease in China: Results From the Sixth China Chronic Disease and Risk Factor Surveillance.中国慢性肾脏病患病率：来自第六次中国慢性病及其危险因素监测的结果。
JAMA Intern Med. 2023 Apr 1;183(4):298-310. doi: 10.1001/jamainternmed.2022.6817.
4
Microbiota analysis in the hemodialysis population - Focusing on Enterobacteriaceae.血液透析人群的微生物群分析——聚焦肠杆菌科。
J Microbiol Immunol Infect. 2023 Apr;56(2):311-323. doi: 10.1016/j.jmii.2022.12.001. Epub 2022 Dec 9.
5
Uremic Toxin-Producing Species Prevail in the Gut Microbiota of Taiwanese CKD Patients: An Analysis Using the New Taiwan Microbiome Baseline.利用新的台湾微生物组基线分析，在台湾慢性肾脏病患者的肠道微生物群中，尿毒症毒素产生菌占优势。
Front Cell Infect Microbiol. 2022 Apr 26;12:726256. doi: 10.3389/fcimb.2022.726256. eCollection 2022.
6
Protein-Bound Uremic Toxins and Immunity.蛋白结合型尿毒症毒素与免疫
Methods Mol Biol. 2021;2325:215-227. doi: 10.1007/978-1-0716-1507-2_15.
7
The Effects of Hemodialysis and Peritoneal Dialysis on the Gut Microbiota of End-Stage Renal Disease Patients, and the Relationship Between Gut Microbiota and Patient Prognoses.血液透析和腹膜透析对终末期肾病患者肠道微生物群的影响以及肠道微生物群与患者预后的关系。
Front Cell Infect Microbiol. 2021 Mar 23;11:579386. doi: 10.3389/fcimb.2021.579386. eCollection 2021.
8
Targeting the gut microbial metabolic pathway with small molecules decreases uremic toxin production.靶向小分子的肠道微生物代谢途径可减少尿毒症毒素的产生。
Gut Microbes. 2020 Nov 9;12(1):1-19. doi: 10.1080/19490976.2020.1823800.
9
Effect of Different Hemodialysis Methods on Microbiota in Uremic Patients.不同血液透析方法对尿毒症患者肠道菌群的影响。
Biomed Res Int. 2020 Jun 19;2020:6739762. doi: 10.1155/2020/6739762. eCollection 2020.
10
Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、区域和国家慢性肾脏病负担，1990-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2020 Feb 29;395(10225):709-733. doi: 10.1016/S0140-6736(20)30045-3. Epub 2020 Feb 13.
Zotero 插件